Start-ups turning to hedge funds

When the private biotechnology company Microbia Inc. closed a $75 million round of funding in February, investors sat up and took notice. Not only because the Cambridge firm had just landed the biggest local round of biotechnology venture financing in two years, but also because a large chunk of the money came from hedge funds. (Full article: 1044 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

• $9.95 1 month archives pass
• $24.95 3 months archives pass
• $74.95 1 year archives pass